Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Daré Bioscience, Inc. (NASDAQ:DARE)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.55 and traded as low as $3.03. Daré Bioscience shares last traded at $3.12, with a volume of 53,089 shares traded.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The company has a market cap of $29.32 million, a P/E ratio of -5.71 and a beta of 1.27. The business’s fifty day moving average is $3.46 and its two-hundred day moving average is $3.54.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.